



PTO/SB/21 (07-06)

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/828,548	RECEIVED CENTRAL FAX CENTER JUN 27 2007
	Filing Date	April 19, 2004	
	First Named Inventor	Schenk, Dale B.	
	Art Unit	1649	
	Examiner Name	Daniel E. Kolker	
Total Number of Pages in This Submission	16	Attorney Docket Number	15270J-004747US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (8 pages) with PTO/SB/08A Form (2 pages) and PTO/SB/08B Form (5 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	Townsend and Townsend and Crew LLP	
Signature		
Printed name	Rosemarie L. Celli	
Date	June 27, 2007	Reg. No. 42,397

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-571-273-8300 on June 27, 2007.			
Signature			
Typed or printed name	Jennifer O'Brien	Date	June 27, 2007

61087706 v1

I hereby certify that this correspondence is being facsimile transmitted to the U. S. Patent and Trademark Office, Fax No. 1-571-273-8300 on June 27, 2007.

Attorney Docket No.: 15270J-004747US
Client Reference No.: 209-US-CIP5C6

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

By: 
Jennifer O'Brien

In re application of:

Dale B. Schenk

Application No.: 10/828,548

Filed: April 19, 2004

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Kolker, D. E.

Art Unit: 1649

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of non-U.S. patent reference nos. 776-875 and 877 can be found in Application No. 09/322,289, filed May 28, 1999 (Attorney Docket No. 15270J-004740US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites the following copending applications which are directed to related subject matter and are commonly owned or under an assignment obligation to be commonly owned:

09/201,430 filed 11/30/98; issued as U.S. 6,787,523 on 09/07/04;

09/724,477 filed 11/28/00; issued as U.S. 6,787,143 on 09/07/04;

09/723,927 filed 11/28/00; issued as U.S. 6,787,138 on 09/07/04;

09/723,762 filed 11/28/00; issued as U.S. 6,787,144 on 09/07/04 ;

Dale B. Schenk
Application No.: 10/828,548
Page 2

PATENT

09/724,102 filed 11/28/00; issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00; issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04; issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04; issued as U.S. 6,818,218 on 11/16/04;
10/815,391 filed 03/31/04; issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
11/108,102 filed 04/15/05;
11/245,524 filed 10/07/05;
10/934,609 filed 09/02/04; issued as U.S. 6,946,135 on 09/20/2005;
11/245,916 filed 10/7/05;
10/933,559 filed 09/02/04; issued as U.S. 6,972,127 on 12/06/05;
10/815,353 filed 03/31/04; issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04; issued as US 7,014,855 on 03/21/06;
10/815,404 filed 03/31/04; issued as U.S. 6,982,084 on 01/03/06;
10/884,892 filed 07/01/04; issued as U.S. 6,962,707 on 11/08/05;
09/322,289 filed 05/28/99;
09/724,319 filed 11/27/00; Appeal Brief filed 10/10/06;
09/723,384 filed 11/27/00; issued as U.S. 6,710,226 on 03/23/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/923,605 filed 08/20/04;
10/923,469 filed 08/20/04;

Dale B. Schenk
Application No.: 10/828,548
Page 3

PATENT

09/724,940 filed 11/28/00; issued as U.S. 6,905,686 on 06/14/05;
09/724,961 filed 11/28/00; issued as U.S. 6,743,427 on 6/1/04;
11/058,757 filed 02/14/05;
09/580,018 filed 05/26/00; issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00; issued as U.S. 6,750,324 on 6/15/04;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00; issued as U.S. 6,787,637 on 09/07/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,000 filed 07/12/04;
10/890,071 filed 07/12/04;
09/723,765 filed 11/28/00;
09/724,567 filed 11/28/00; issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00; issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00; issued as U.S. 6,936,246 on 08/30/05; and
09/979,952 filed 04/09/02 (U.S. National Stage of PCT/US00/15239
filed 06/01/00); issued as U.S. 6,913,745 on 07/05/05.

Applicant also cites the following copending applications directed to related
subject matter but subject to different assignment:

10/010,942 filed 12/06/01; Issued as US 7,189,819 on 03/13/07;
10/789,273 filed 2/27/04;
10/232,030 filed 08/30/02;
10/388,389 filed 03/12/03; issued as US 7,179,892 on 02/20/07;

Dale B. Schenk
Application No.: 10/828,548
Page 4

PATENT

10/388,214 filed 03/12/03;
10/858,855 filed 06/01/04;
10/771,174 filed 02/04/04;
11/260,047 filed 10/26/05;
11/304,986 filed 12/15/05;
11/305,889 filed 12/15/05;
11/305,899 filed 12/15/05;
11/303,478 filed 12/15/05;
11/304,072 filed 12/15/05;
60/736,119 filed 11/10/05;
60/735,687 filed 11/10/05;
10/544,093 filed 08/01/05 (U.S. National Stage of PCT/US04/02856
filed 01/31/04);
11/342,353 filed 01/27/06;
10/583,503 filed 06/16/06
11/454,772 filed 06/16/06.
11/516,724 filed 09/05/06;
11/520,438 filed 09/12/06; and
60/793,014 filed 04/18/06.

Applicant further cites the following commonly owned abandoned applications or
abandoned applications under an assignment obligation to be commonly owned which are
directed to related subject matter:

60/067,740 filed 12/02/97;

Dale B. Schenk
Application No.: 10/828,548
Page 5

PATENT

60/080,970 filed 04/07/98;
10/928,926 filed 08/27/04;
09/580,015 filed 05/26/00;
10/889,999 filed 04/12/04;
09/580,019 filed 05/26/00;
09/724,291 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302
filed 06/01/00);
09/579,690 filed 05/26/00;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99,
09/723,544 filed 11/28/00.
09/497,553 filed 02/03/00;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,495 filed 11/27/00;

Dale B. Schenk
Application No.: 10/828,548
Page 6

PATENT

10/788,666 filed 02/27/04;

09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810
filed 05/26/00);

10/822,968 filed 04/12/04;

10/823,463 filed 04/12/04;

10/890,024 filed 04/12/04;

10/890,070 filed 07/12/04;

10/923,267 filed 08/20/04;

10/934,819 filed 09/02/04; and

11/396,391 filed 03/30/2006.

Applicant also cites the following abandoned applications directed to related
subject matter but subject to different assignment:

10/703,713 filed 11/07/03;

10/704,070 filed 11/07/03;

11/396,417 filed 03/30/06;

11/413,638 filed 04/28/06;

60/251,892 filed 12/06/00;

60/444,150 filed 02/01/03;

60/616,474 filed 10/05/04;

60/530,481 filed 12/17/03;

60/474,654 filed 05/30/03;

60/363,751 filed 03/12/02.

60/622,525 filed 10/26/04;

Dale B. Schenk
Application No.: 10/828,548
Page 7

PATENT

60/636,684 filed 12/15/04;
60/636,842 filed 12/15/04;
60/637,253 filed 12/16/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04;
60/736,045 filed 11/10/05;
60/691,821 filed 06/17/05; and
60/648,631 filed 01/28/05.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she are invited to call the undersigned who will be happy to supply them.


Dale B. Schenk
Application No.: 10/828,548
Page 8

PATENT

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf
61087856 v1

JUN 27 2007

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	855	7,195,761	03-27-2007	Holtzman et al.	
	878	7,189,819	03-13-2007	Basi et al.	
	879	7,179,892	02-20-2007	Basi et al.	
	880	7,014,855	03-21-2006	Schenk	
	881	6,982,084	01-03-2006	Schenk	
	785	2005/0249725 A1	11-10-2005	Schenk et al.	
	866	6,962,984	11-08-2005	Ishiwata et al.	
	784	2005/0118651 A1	06-02-2005	Basi et al.	
	805	2004/0197324 A1	10-07-2004	Jun et al.	
	882	6,787,139	09-07-2004	Schenk	
	783	2004/0087777 A1	05-06-2004	Basi et al.	
	782	2004/0082762 A1	04-29-2004	Basi et al.	
	849	6,727,349	04-27-2004	LaRosa et al.	
	870	2003/0207828 A1	11-06-2003	Ishiwata et al.	
	804	2003/0202972 A1	10-30-2003	James et al.	
	869	2003/0135035 A1	07-17-2003	Shannon	
	871	2003/0092145 A1	05-15-2003	Jira et al.	
	777	6,270,757	08-07-2001	Wame	
	778	6,267,958	07-31-2001	Andya et al.	
	795	6,210,671	04-03-2001	Co	
	867	5,866,129	02-02-1999	Chang et al.	
	860	5,858,981	01-12-1999	Schreiber et al.	
	779	5,770,700	06-23-1998	Webb et al.	
	780	5,744,132	04-28-1998	Wame et al.	
	876	5,731,284	03-24-1998	Williams	
	781	5,385,887	01-31-1995	Yim et al.	
	868	5,245,015	09-14-1993	Fung et al.	
	819	5,227,159	07-13-1993	Miller	

Examiner Signature	Date Considered
-----------------------	--------------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
61085640

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 7

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	853	EP	921 189	B1	01-12-2005			
	842	EP	1 481 992	A2, A3	12-01-2004			
	786	EP	758 901	B1	02-26-1997			
	787	EP	758 248	B1	02-19-1997			
	802	EP	597 101	A1	05-18-1994			
	848	WO	05/026211	A2, A3	03-24-2005			
	847	WO	04/071408	A2	08-26-2004			
	797	WO	04/055164	A2	07-01-2004			
	846	WO	04/044204	A2, A3	05-27-2004			
	796	WO	03/105894	A1	12-24-2003			
	845	WO	03/072036	A2, A3	09-04-2003			
	799	WO	03/39485	A2	05-15-2003			
	803	WO	03/16466	A2	02-27-2003			
	788	WO	03/15691	A2	02-27-2003			
	798	WO	03/09817	A2	02-06-2003			
	827	WO	02/96937	A2	12-05-2002			
	789	WO	01/05355	A2	01-25-2001			
	813	WO	97/03192	A3	01-30-1997			
	854	WO	95/07301	A1	03-16-1995			
	814	WO	94/00153	A1	01-06-1994			
	821	WO	91/16928	A1	11-14-1991			

 Examiner
 Signature

 Date
 Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
 61085640

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
		Attorney Docket Number	15270J-004747US
Sheet	3	of	7

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	875	ARD et al., "Scavenging of Alzheimer's Amyloid β -Protein by Microglia in Culture," <u>J. Neuroscience Research</u> , 43:190-202 (1996).	
	790	BALES et al., "Administration of an Anti-A β Fab Fragment to APP ^{V717F} Transgenic Mice Reduces Neuritic Plaque," Abstract P\$-396, Page S587, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based	
	858	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A β antibody," <u>J. Clin. Invest.</u> , 116(3):825-832 (2006).	
	840	BORENSTEIN, S., "New Alzheimer's vaccine to be tested on people soon, Early experiments on mice halted condition; considered safe for humans," <u>Free Press</u> , 7/23/01.	
	832	BROADWELL et al., "Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system," <u>Exp. Neurol.</u> , 120(2):245-263 (1993).	
	824	BROOKMEYER et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset," <u>Am. J. Public Health</u> , 88:1337-1342 (1998).	
	791	BUSSIERE et al., "Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A β Immunotherapy on Their Clearance," <u>Am. J. Pathology</u> , 165(3):987-995 (2004).	
	823	CASELL et al., "Demography and Epidemiology of Age-Associated Neuronal Impairment," chapter 4, pages 31-50 from <u>Functional Neurobiology of Aging</u> , Hof et al., eds., Academic Press (2001).	
	859	COMERY et al., "Passive Immunization Against β -Amyloid Leads to Acute Cognition Improvement," <u>Society for Neuroscience</u> , abstract, Washington DC, 11/12-16/05.	
	836	DAS et al., "Reduced effectiveness of A β -42 immunization in APP transgenic mice with significant amyloid deposition," <u>Neurobiology of Aging</u> , 22:721-727 (2001).	
	861	DE FELICE et al., " β -Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease," <u>Cell Mol. Neurobiol.</u> , 22(5/6):545-563 (2002).	
	862	DISIS et al., "Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines," <u>Blood</u> , 88(1):202-210 (1996).	
Examiner Signature			Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61085640

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Sheet 4 of 7	Attorney Docket Number	15270J-004747US	

817	DU et al., "α ₂ -Macroglobulin as a β-Amyloid Peptide-Binding Plasma Protein," <u>J. Neurochemistry</u> , 69(1):299-305 (1997).	
811	European Search Report of 5/22/06 for European Application 06075704.4-2107.	
812	European Search Report of 5/22/06 for European Application 06075479.3-2107.	
852	European Search Report of 1/16/07 for European Application 04776252.1-2405.	
831	FUKUTANI et al., "Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val->Ile) mutation cases: A morphometric investigation," <u>J. Neurologic Sci.</u> , 149:177-184 (1997).	
873	GEYLIS et al., "Immunotherapy of Alzheimer's disease 9AD: From murine models to anti-amyloid beta 9Ab) human monoclonal antibodies," <u>Autoimmunity Rev.</u> , 5:33-39 (2000).	
807	HARA et al., "Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease," <u>J. Alzheimer's Disease</u> , 6:483-488 (2004).	
792	KAJKOWSKI et al., "β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module," <u>J. Biol. Chem.</u> , 276(22):18748-18756 (2001).	
834	KALBACK et al., "APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques," <u>Biochemistry</u> , 41:922-928 (2002).	
863	KIMCHI et al., "Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy," <u>J. Neuropath Exp. Neurol.</u> , 60(3):274-279 (2001).	
843	KLYUBIN et al., "Anti-Aβ Antibodies Prevent Block of Long-Term Potentiation In the CA1 Area of Rat Hippocampus <i>In Vivo</i> by naturally Produced Aβ Oligomers," <u>Neurobiology of Aging</u> , 25:S224-S225, abstract P2-004, pages S224-S225 (2004).	
794	KOFLER et al., "Immunoglobulin κ Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies in Lupus Mice," <u>J. Clin. Invest.</u> , 82:852-860 (1988).	
826	KUBY, J., eds., page 123 from <u>Immunology, Third Edition</u> , W.H. Freeman & co., (1997).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61085640

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5

of

7

Complete If Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-004747US

833	KUO et al., "Comparative Analysis of Amyloid- β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains," <u>J. Biol. Chem.</u> , 276(16):12991-12998 (2001).
816	LaDu et al., "Isoform-specific Binding of Apolipoprotein E to β -Amyloid," <u>J. Biol. Chem.</u> , 269(38):23403-23406 (1994).
822	Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006.
841	OKIE, S., "Promising Vaccine Targets Ravager of Minds," <u>Washington Post</u> , page A01, 5/8/01.
808	OKURA et al., "Nonviral A β DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety," <u>PNAS</u> , 103(25):9619-9624 (2006).
829	PARDRIDGE et al., "The Blood-Brain Barrier: Bottleneck in Brain Drug Development," <u>J. Am. Soc. Exp. Neurotherapeutics</u> , 2:3-14 (2005).
806	PCT Search Report of 8/11/06 for application PCT/US2006/002837.
850	PCT Search Report of 8/8/06 for application PCT/US2005/045515.
872	PCT Search Report of 4/6/06 and Written Opinion of 4/8/06 for application PCT/US04/44093.
864	PIERA et al., "Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn)," <u>Int. J. Cancer</u> , 55(1):148-152 (1993).
877	PLUCKTHUN, A., "Mono- and Bivalent Antibody Fragments Produced in <i>Escherichia coli</i> : Engineering, Folding and Antigen Binding," <u>Immunological Reviews</u> , 130:151-188 (1992).
837	Press Release, "Alzheimer's vaccine developer awarded Potamkin Prize," American Academy of Neurology, 5/7/01.
809	QU et al., "A β ₄₂ gene vaccination reduces brain amyloid plaque burden in transgenic mice," <u>J. Neurological Sciences</u> , 244:151-158 (2006).
838	ROSENBERG, R. N., "The Potamkin Prize for Pick's, Alzheimer's Disease and Related Disorders," pages 1-5.
865	ROSES, A.D., "Apoplipoprotein E alleles as risk factors in Alzheimer's disease," <u>Annu. Rev. Med.</u> , 47:387-400 (1996).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61085640

JUN 27 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Sheet 6 of 7	Attorney Docket Number	15270J-004747US	

851	SALDANHA et al., "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <u>Molecular Immunology</u> , 36:709-719 (1999).
856	SEUBERT et al., "Antibody Capture of Soluble A β does not Reduce Cortical A β Amyloidosis in the PDAPP Mouse," <u>Neurodegenerative Diseases</u> , (2007).
818	SHINKAI et al., "Amyloid β -Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels," <u>Ann. Neurol.</u> , 38:421-428 (1995).
828	Signet Laboratories, Inc., Product data sheet for mouse monoclonal clone 6E10, revised 7/13/05.
874	SOTO et al., "The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis," <u>Biochem. J.</u> , 314:701-707 (1996).
839	TRAVIS, J., "A Vaccine for Alzheimer's Disease?@," <u>Science News Online</u> , 156(2) pages 1-3 downloaded from internet (1999).
857	TRAVIS, J., "Saving the Mind Faces High Hurdles," <u>Science</u> , 309:731-734 (2005).
844	UniProtKB/Swiss-Prot entry P18525, pages 1-3 downloaded from http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525 on 2/8/97, "HV54_Mouse" (11/1/90).
815	URMONEIT et al., "Cerebrovascular Smooth Muscle Cells Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy," <u>Laboratory Investigation</u> , 77(2):157-166 (1997).
835	VAN LEUVEN, F., "Single and multiple transgenic mice as models for Alzheimer's disease," <u>Progress in Neurobiology</u> , 61:305-312 (2000).
800	VIDANOVIC et al., "Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation," <u>DIE PHARMAZIE</u> , 58(6):399-404 (2003).
801	WANG, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <u>Int. J. Pharmaceutics</u> , 185(2):129-188 (1999).
793	ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid- β : Potential Therapeutic for Alzheimer's Disease," Abstract P4-420, Page S593, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61085640

RECEIVED
CENTRAL FAX CENTER

JUN 27 2007

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/828,548
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
		Attorney Docket Number	15270J-004747US
Sheet	7	of	7

825	ZHANG et al., "Specialized Applications, Purification of Recombinant Proteins and Study of Protein Interaction by Epitope Tagging," <u>Current Protocols in Mol. Biol.</u> , Supp 41, pages 10.15.1 through 10.15.9 (1998).
810	ZHANG et al., "A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β -amyloid plaques in a mouse model of Alzheimer's disease," <u>Neurobiology of Disease</u> , 14:365-379 (2003).

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
61085640